Tonggu, Lige http://orcid.org/0000-0002-0033-556X
Wisedchaisri, Goragot http://orcid.org/0000-0002-6967-5925
Gamal El-Din, Tamer M. http://orcid.org/0000-0002-7406-7393
Lenaeus, Michael J.
Logan, Matthew M.
Toma, Tatsuya
Du Bois, Justin http://orcid.org/0000-0001-7847-1548
Zheng, Ning http://orcid.org/0000-0002-1039-1581
Catterall, William A. http://orcid.org/0000-0001-5509-3580
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R35 NS111573)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL112808, K08 HL145630, R01 HL112808)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01 GM117263)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Howard Hughes Medical Institute (N/A)
Article History
Received: 5 October 2023
Accepted: 8 February 2024
First Online: 14 March 2024
Competing interests
: J.D. is a cofounder and holds equity shares in SiteOne Therapeutics, Inc., a start-up company interested in developing subtype-selective modulators of Na<sub>V</sub>s. The other authors declare no competing interests.